Eli Lilly and (NYSE:LLY) has been given a $73.00 target price by BMO Capital Markets in a note issued to investors on Tuesday. The firm presently has a “sell” rating on the stock. BMO Capital Markets’ price target indicates a potential downside of 15.18% from the company’s current price.

Several other research analysts have also recently issued reports on LLY. Jefferies Group reissued a “buy” rating and set a $89.00 target price on shares of Eli Lilly and in a research note on Thursday, August 31st. Leerink Swann lifted their target price on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Piper Jaffray Companies reissued an “overweight” rating and set a $105.00 target price (up previously from $103.00) on shares of Eli Lilly and in a research note on Friday, September 8th. Goldman Sachs Group reissued a “buy” rating and set a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Finally, BidaskClub downgraded Eli Lilly and from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Eli Lilly and presently has an average rating of “Hold” and a consensus target price of $90.25.

Shares of Eli Lilly and (NYSE LLY) traded up $0.48 during trading on Tuesday, hitting $86.06. The company had a trading volume of 3,876,686 shares, compared to its average volume of 3,672,667. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The company has a market capitalization of $93,945.43, a P/E ratio of 20.86, a PEG ratio of 1.87 and a beta of 0.35. Eli Lilly and has a one year low of $66.39 and a one year high of $89.09.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the prior year, the firm posted $0.88 earnings per share. The company’s quarterly revenue was up 9.0% on a year-over-year basis. equities analysts predict that Eli Lilly and will post 4.21 EPS for the current year.

In related news, major shareholder Lilly Endowment Inc sold 195,000 shares of the company’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $85.14, for a total value of $16,602,300.00. Following the completion of the transaction, the insider now owns 123,513,247 shares of the company’s stock, valued at approximately $10,515,917,849.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 592,003 shares of company stock worth $50,246,641. Company insiders own 0.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in LLY. Accredited Investors Inc. grew its position in Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after acquiring an additional 14 shares during the period. Northwest Quadrant Wealth Management LLC grew its position in Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after acquiring an additional 19 shares during the period. Oakworth Capital Inc. grew its position in Eli Lilly and by 0.3% in the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after acquiring an additional 20 shares during the period. Sfmg LLC grew its position in Eli Lilly and by 0.5% in the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after acquiring an additional 20 shares during the period. Finally, Jackson Grant Investment Advisers Inc. grew its position in Eli Lilly and by 0.7% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after acquiring an additional 24 shares during the period. 76.43% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/05/eli-lilly-and-lly-given-a-73-00-price-target-by-bmo-capital-markets-analysts.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.